US waives 100% tariff on select Indian speciality drugs
The United States has waived 100% tariffs on certain specialty pharmaceutical products and their ingredients from India, announced by the US Commerce Department. This waiver applies to 20 countries, including India, in response to President Donald Trump's April 2 directive to adjust pharmaceutical imports. The zero-tariff exemption covers rare disease treatments, nuclear medicines, plasma-derived therapies, fertility drugs, cell and gene therapies, antibody-drug conjugates (ADCs), and animal medicines.
The waiver also extends to ingredients used in these products. India contributes significantly to US pharmaceutical exports, with $30.46 billion worth of drugs and pharmaceutical products traded in the 2024-25 fiscal year. The Commerce Department defines orphan drugs as those designated for rare diseases or conditions, and the waiver applies to these drugs and their ingredients.
Companies can seek tariff relief for speciality drugs addressing urgent US health needs, subject to review by the Commerce Department in consultation with the US Trade Representative and the Department of Health and Human Services.
Written by urgent.news from The Indian Express's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
